Celentyx Ltd | Immunology CRO
  • Home
  • Immunology Assays
    • Antigen-specific Assays
    • B Cells
    • Fibroblasts
    • Haemolysis Testing
    • Human microglia
    • Macrophages/Monocytes
    • Granulocytes (neutrophils and eosinophils)
    • NK Cells
    • Phagocytosis Assays
    • Regulatory T cells
    • Spheroid Killing Assays
    • Suppression Assays
    • T Cell Activation Assays
    • T Cell Exhaustion Assays
    • TIL and dissociated tumour cell assays
    • Tumour Cell Killing
  • Therapeutic Area
    • Autoimmunity & Inflammation
    • COVID-19
    • Fibrosis
    • Immuno-oncology
    • Neuroinflammation
  • Services
    • Assays on Patient Cells
    • Bespoke Services & Assay Development
    • CyTOF
    • Cytokine Release Assays
    • ELISA
    • ELISpot
    • ELLA
    • Flow Cytometry
    • Imaging: High-content
    • Intracellular Cytokine Staining
    • Luminex
    • Phosphoflow
    • Seahorse Metabolic Assays
  • About
    • People
    • Publications
    • News
    • Careers
  • Contact
  • Blog

Insights & Updates 

Scientific perspectives, research highlights and the latest news from Celentyx.​

Celentyx at ELRIG 2026

30/10/2026

0 Comments

 
​Celentyx was pleased to take part in ELRIG Drug Discovery 2026, held on 14–15 October at ExCeL London.
Picture
​Dr Omar Qureshi at ELRIG Drug Discovery 2026

Our Chief Scientific Officer, Dr Omar Qureshi, presented our work on human microglial models and their applications in translational neuroinflammation drug discovery.

Microglia play a central role in neuroinflammation, making human-relevant models valuable tools for investigating disease mechanisms and supporting the development of new therapeutics.

The conference brought together researchers from across the drug discovery community, providing an opportunity to share our work and discuss the role of human microglial models in advancing neuroinflammation research.
0 Comments

New publication from Celentyx in Brain: Advancing the case for P2X7 receptor antagonism in neuroinflammation

13/10/2026

0 Comments

 
Celentyx is proud to have contributed human translational evidence supporting P2X7 receptor antagonism as a powerful therapeutic strategy to combat neuroinflammation (https://doi.org/10.1093/brain/awag068).

Published in Brain, this research provides key evidence that targeting the human purinergic P2X7 receptor can limit hostile, pathology-driven pro-inflammatory responses in human models of traumatic brain injury (TBI).

Through a rigorous pharmacological investigation leveraging Celentyx’s advanced Neuroinflammation Platforms, including a human cellular microglial model alongside human functional brain slices, the study demonstrates the translational potential of the clinical-stage, CNS-penetrant P2X7 receptor antagonist, JNJ-54175446, to reduce secretion of relevant neuroinflammatory cytokines.

These findings mark an important step forward in understanding how P2X7 receptor antagonism may be harnessed to modulate microglia-driven inflammation following TBI. More broadly, they strengthen the scientific rationale for investigating this pathway across neurological and psychiatric diseases in which dysregulated neuroinflammation is implicated.

At Celentyx, we are committed to accelerating the discovery and development of therapies for diseases mediated via the immune system. Our extensive portfolio of human advanced in vitro models enables investigation of therapeutic mechanisms and evaluate drug candidates targeting immune system pathways, including those relevant to human microglia and neuroinflammation.

Download the full paper here.

Picture
0 Comments

    Author

    The Celentyx team shares insights on immunology and drug discovery, alongside our latest research, news and activities.

    Archives

    November 2026
    October 2026

    Categories

    All
    Celentyx News & Events
    Our Publications
    Research Spotlight

    RSS Feed

    CONTACT US

Submit
Web Hosting by Bluehost
  • Home
  • Immunology Assays
    • Antigen-specific Assays
    • B Cells
    • Fibroblasts
    • Haemolysis Testing
    • Human microglia
    • Macrophages/Monocytes
    • Granulocytes (neutrophils and eosinophils)
    • NK Cells
    • Phagocytosis Assays
    • Regulatory T cells
    • Spheroid Killing Assays
    • Suppression Assays
    • T Cell Activation Assays
    • T Cell Exhaustion Assays
    • TIL and dissociated tumour cell assays
    • Tumour Cell Killing
  • Therapeutic Area
    • Autoimmunity & Inflammation
    • COVID-19
    • Fibrosis
    • Immuno-oncology
    • Neuroinflammation
  • Services
    • Assays on Patient Cells
    • Bespoke Services & Assay Development
    • CyTOF
    • Cytokine Release Assays
    • ELISA
    • ELISpot
    • ELLA
    • Flow Cytometry
    • Imaging: High-content
    • Intracellular Cytokine Staining
    • Luminex
    • Phosphoflow
    • Seahorse Metabolic Assays
  • About
    • People
    • Publications
    • News
    • Careers
  • Contact
  • Blog